The Alex study reported that regardless of the EML4-ALK variant, the progression-free survival (PFS) of untreated ALK-positive NSCLC treated with alectinib was better than that of crizotinib [25]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.